ERBB2 and breast carcinoma: Besides, monotherapy with abemaciclib was also permitted for HR‐positive/HER2‐negative advanced breast cancer after prior endocrine therapy and 1–2 chemotherapy regimens according to an ORR of 19.7% in the MONARCH‐1 trial.405